Business
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016.
About this update from Fluoropharma Medical Inc
[{"type":"text","content":"\nFluoroPharma Medical Announces Details for Investor Call on June 22, 2016\n\nFluoroPharma Medical Announces Details for Investor Call on June 22, 2016\n\nMONTCLAIR, NJ--(Marketwired - June 17, 2016) - FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on recent company news and address questions from investors. Questions may be submitted prior to the call by posting to [email protected]. Participants who would like to ask questions during the question and answer session must participate by telephone. Participants are encouraged to dial-in fifteen minutes before the conference call begins. Investors and the public are invited to access the live audio cast:Event: FluoroPharma Medical, Inc. 2Q Investor CallDate and Time: Wednesday, June 22nd 4:30 PM EDTLive participant dial-in (Toll-free US and Canada): 877-407-8129Live participant dial-in (International): 201-493-6710An audio replay link will be available after the completion of the call on the Investor Relations section of the Company's website: http://www.fluoropharma.com/About FluoroPharma MedicalFluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes. FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.comForward-Looking StatementsExcept for historical informati...